Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow-On Biologics Guidance Will Follow Public Workshop, FDA Tells Senate

Executive Summary

FDA's draft guidance on follow-on biologics will be preceded by a scientific workshop on the topic, Acting Commissioner Lester Crawford told the Senate Judiciary Committee June 23

You may also be interested in...



FDA Follow-On Biologics Public Meeting Slated For Early ’05

FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics

FDA Follow-On Biologics Public Meeting Slated For Early ’05

FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics

Follow-On Biologics Will Rely On “Case-By-Case” Approach – Rep. Waxman

FDA's development of a guidance for follow-on versions of insulin and human growth hormone will be a key milestone in demonstrating the agency's ability to implement a "case-by-case" approach to "generic" biologics, Rep. Henry Waxman (D-Calif.) said

Related Content

UsernamePublicRestriction

Register

PS044231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel